FY2024 EPS Estimates for YMAB Raised by Cantor Fitzgerald

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Analysts at Cantor Fitzgerald increased their FY2024 earnings per share estimates for Y-mAbs Therapeutics in a research note issued on Monday, November 11th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($0.66) per share for the year, up from their prior estimate of ($0.67). Cantor Fitzgerald has a “Overweight” rating and a $20.00 price objective on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.64) per share.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. During the same quarter in the previous year, the firm posted ($0.18) EPS.

A number of other analysts have also recently weighed in on YMAB. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Friday. BMO Capital Markets dropped their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. Morgan Stanley reduced their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 13th. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. Finally, Wedbush reissued an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.14.

Y-mAbs Therapeutics Stock Down 3.9 %

Y-mAbs Therapeutics stock opened at $11.14 on Thursday. The firm has a fifty day moving average of $13.98 and a 200-day moving average of $13.09. Y-mAbs Therapeutics has a 52-week low of $5.04 and a 52-week high of $20.90. The firm has a market capitalization of $498.96 million, a P/E ratio of -20.63 and a beta of 0.68.

Insider Activity

In related news, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the sale, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. This represents a 14.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Thomas Gad sold 65,000 shares of Y-mAbs Therapeutics stock in a transaction on Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the transaction, the insider now directly owns 97,681 shares of the company’s stock, valued at approximately $1,315,763.07. This represents a 39.96 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 100,000 shares of company stock worth $1,338,100. 22.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC grew its position in Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after purchasing an additional 74,452 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Y-mAbs Therapeutics during the third quarter worth approximately $178,000. Millennium Management LLC grew its holdings in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after buying an additional 67,233 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after acquiring an additional 65,732 shares during the period. Finally, Ameritas Investment Partners Inc. raised its stake in Y-mAbs Therapeutics by 39.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after acquiring an additional 1,056 shares in the last quarter. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.